Literature DB >> 1618748

The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A.

M Z Kounnas1, R E Morris, M R Thompson, D J FitzGerald, D K Strickland, C B Saelinger.   

Abstract

The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha 2 MR/LRP) is a large cell-surface glycoprotein consisting of a 515-kDa and an 85-kDa polypeptide; this receptor is thought to be responsible for the binding and endocytosis of activated alpha 2-macroglobulin and apoE-enriched beta-very low density lipoprotein. A similar high molecular weight glycoprotein has been identified as a potential receptor for Pseudomonas exotoxin A (PE). We demonstrate that the alpha 2 MR/LRP and the PE-binding glycoprotein have a similar mobility upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis and are immunologically indistinguishable. Furthermore, affinity-purified alpha 2 MR/LRP binds specifically to PE but not to a mutant toxin defective in its ability to bind cells. The 39-kDa receptor-associated protein, which blocks binding of ligands to alpha 2 MR/LRP, also prevents binding and subsequent toxicity of PE for mouse fibroblasts. The concentration of receptor-associated protein that was required to reduce binding and toxicity to 50% was approximately 14 nM, a value virtually identical to the KD measured for the interaction of receptor-associated protein with the purified receptor. Overall, the studies strongly suggest that the alpha 2 MR/LRP is responsible for internalizing PE.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1618748

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.486


  96 in total

Review 1.  LRP: a multifunctional scavenger and signaling receptor.

Authors:  J Herz; D K Strickland
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

2.  Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated.

Authors:  M Tolar; M A Marques; J A Harmony; K A Crutcher
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

Review 3.  Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.

Authors:  Robert J Kreitman; Ira Pastan
Journal:  Clin Cancer Res       Date:  2011-10-15       Impact factor: 12.531

Review 4.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

5.  The myeloid differentiation factor 88 is dispensable for the development of a delayed host response to Pseudomonas aeruginosa lung infection in mice.

Authors:  M R Power; J S Marshall; M Yamamoto; S Akira; T-J Lin
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

6.  Localization of basic residues required for receptor binding to the single alpha-helix of the receptor binding domain of human alpha2-macroglobulin.

Authors:  W Huang; K Dolmer; X Liao; P G Gettins
Journal:  Protein Sci       Date:  1998-12       Impact factor: 6.725

Review 7.  Novel bacterial ADP-ribosylating toxins: structure and function.

Authors:  Nathan C Simon; Klaus Aktories; Joseph T Barbieri
Journal:  Nat Rev Microbiol       Date:  2014-07-14       Impact factor: 60.633

8.  Ligand selectivity of 105 kDa and 130 kDa lipoprotein-binding proteins in vascular-smooth-muscle-cell membranes is unique.

Authors:  V N Bochkov; V A Tkachuk; M P Philippova; D V Stambolsky; F R Bühler; T J Resink
Journal:  Biochem J       Date:  1996-07-01       Impact factor: 3.857

9.  A novel synthetic bipartite carrier protein for developing glycotope-based vaccines.

Authors:  Hsiao-Ling Chiang; Chi-Yu Lin; Fan-Dan Jan; Yaoh-Shiang Lin; Chia-Tse Hsu; Jacqueline Whang-Peng; Leroy F Liu; Shin Nieh; Chun-Cheng Lin; Jaulang Hwang
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

10.  Regulation of macrophage alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein by lipopolysaccharide and interferon-gamma.

Authors:  J LaMarre; B B Wolf; E L Kittler; P J Quesenberry; S L Gonias
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.